Biogen Inc. vs Alkermes plc: A Decade of Revenue Dynamics

In the ever-evolving landscape of biotechnology, Biogen Inc. and Alkermes plc have carved distinct paths over the past decade. From 2014 to 2023, Biogen consistently outperformed Alkermes in terms of revenue, peaking in 2019 with a staggering 14.4 billion USD. However, the subsequent years saw a decline, with 2023 revenues dropping to approximately 9.8 billion USD, marking a 32% decrease from its peak.

Conversely, Alkermes exhibited a steady growth trajectory, culminating in a 169% increase in revenue from 2014 to 2023. This growth is particularly notable in 2023, where Alkermes achieved its highest revenue of 1.66 billion USD, reflecting a robust 50% increase from the previous year.

These trends underscore the dynamic nature of the biotech industry, where strategic innovation and market adaptation are key to sustained success.